pyrroles has been researched along with tivozanib in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Figlin, RA | 1 |
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
3 review(s) available for pyrroles and tivozanib
Article | Year |
---|---|
A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antigens, Neoplasm; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Dendritic Cells; Electroporation; Everolimus; Humans; Immunotherapy, Active; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Pyrroles; Quinolines; RNA, Neoplasm; Signal Transduction; Sirolimus; Sunitinib; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2014 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |